$AIMD

TSAI CHUN-JUNG sold $2K of AIMD

TSAI CHUN-JUNG sold 1,082 shares of Ainos, Inc. (AIMD) at $1.55 on 2026-05-22.

Original reporting
SEC EDGAR · TSAI CHUN-JUNG
Published May 27, 2026, 11:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 28, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AIMD
Neutral
medium confidence
Mentioned
$AIMD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIMDNeutralMed
01

Why it matters

Insider selling can pressure sentiment, especially for small-cap names, but the filing lacks any fundamental trigger (no earnings, trial, contract, or deal).

02

Market read

Traders may watch for follow-on insider activity or unusual volume, but this alone is not a fundamental catalyst.

03

What to watch

No 10b5-1 plan is cited, so traders may over-interpret intent; also, the remaining holdings (685,917 shares) suggest continued insider exposure.

Relevance 7/10Timing: Immediate (new SEC Form 4 disclosure dated 2026-05-27 for a sale on 2026-05-22).

Background

The article is an SEC Form 4 insider transaction disclosure for Ainos, Inc. (AIMD).

Company-level read

Ticker impact

$AIMDNeutralMedium confidence
Context

SEC Form 4 shows director TSAI CHUN-JUNG sold 1,082 shares of Ainos, Inc. (AIMD) in an open-market transaction at $1.55.

Expected impact

Likely modest negative/neutral short-term drift; magnitude uncertain because it’s a small, single-insider sale with no 10b5-1 plan noted.

Evidence & confidence

The filing is a disclosed insider sale (not a buy) and can affect sentiment, but the article provides no earnings, guidance, or fundamental change.

Market effects

Minimal—this is company-specific insider activity with no sector-wide catalyst mentioned.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio management; without a stated reason, it may not reflect bearish fundamentals.

Key entities

  • Ainos, Inc.

    Subject of the SEC Form 4 insider sale disclosure.

  • TSAI CHUN-JUNG

    Director who sold 1,082 shares of AIMD at $1.55/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AIMDHigh

Ainos Shares Rise 6.9% After Receiving Initial AI Nose Semiconductor Orders

Ainos Inc. (AIMD) shares rose 6.9% after receiving initial commercial orders for its AI Nose platform from a semiconductor manufacturer. The orders follow validation activities and represent a shift to commercial deployment. The company expects revenue from these orders in the second half of 2026. Ainos also reported its chemical dataset has surpassed one billion records, up from 878 million in August.

$AIMDHigh

Ainos stock jumps on AI Nose orders from semiconductor sector

Ainos Inc (AIMD) shares rose 6.9% premarket after receiving initial commercial orders for its AI Nose platform from a semiconductor manufacturer. The orders mark a shift to commercial deployment, with revenue expected from late 2026. The company also announced its real-world chemical dataset surpassed 1 billion records, up from 878 million in August. AIMD's technology is used in semiconductor manufacturing for chemical perception and data collection.

$AIMDLow

Ainos, Inc. (AIMD): Results of Operations and Financial Condition

Ainos, Inc. (AIMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”) today announced results for the second quarter en

$AIMDMed

Ainos, Inc.: VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations

Ainos, Inc. (NASDAQ:AIMD) said VASRO GmbH highlighted its AI Nose platform’s expansion into live emergency department operations. VASRO reports a research program at an Asia academic medical center to generate 2,500+ hours of emergency-department environmental scent data for overcrowding early warning and respiratory infection risk analysis. The initiative broadens evaluations beyond industrial settings and supports Ainos’ Smell Language Model development.